"Neuroblastoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)
Descriptor ID |
D009447
|
MeSH Number(s) |
C04.557.465.625.600.590.650.550 C04.557.470.670.590.650.550 C04.557.580.625.600.590.650.550
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Neuroblastoma".
- Diseases [C]
- Neoplasms [C04]
- Neoplasms by Histologic Type [C04.557]
- Neoplasms, Germ Cell and Embryonal [C04.557.465]
- Neuroectodermal Tumors [C04.557.465.625]
- Neoplasms, Neuroepithelial [C04.557.465.625.600]
- Neuroectodermal Tumors, Primitive [C04.557.465.625.600.590]
- Neuroectodermal Tumors, Primitive, Peripheral [C04.557.465.625.600.590.650]
- Neuroblastoma [C04.557.465.625.600.590.650.550]
- Neoplasms, Glandular and Epithelial [C04.557.470]
- Neoplasms, Neuroepithelial [C04.557.470.670]
- Neuroectodermal Tumors, Primitive [C04.557.470.670.590]
- Neuroectodermal Tumors, Primitive, Peripheral [C04.557.470.670.590.650]
- Neuroblastoma [C04.557.470.670.590.650.550]
- Neoplasms, Nerve Tissue [C04.557.580]
- Neuroectodermal Tumors [C04.557.580.625]
- Neoplasms, Neuroepithelial [C04.557.580.625.600]
- Neuroectodermal Tumors, Primitive [C04.557.580.625.600.590]
- Neuroectodermal Tumors, Primitive, Peripheral [C04.557.580.625.600.590.650]
- Neuroblastoma [C04.557.580.625.600.590.650.550]
Below are MeSH descriptors whose meaning is more specific than "Neuroblastoma".
This graph shows the total number of publications written about "Neuroblastoma" by people in this website by year, and whether "Neuroblastoma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1996 | 2 | 1 | 3 |
1997 | 3 | 1 | 4 |
1998 | 2 | 1 | 3 |
1999 | 0 | 2 | 2 |
2000 | 6 | 2 | 8 |
2001 | 4 | 1 | 5 |
2002 | 2 | 4 | 6 |
2003 | 2 | 0 | 2 |
2004 | 4 | 2 | 6 |
2005 | 4 | 1 | 5 |
2006 | 4 | 0 | 4 |
2007 | 6 | 1 | 7 |
2008 | 6 | 3 | 9 |
2009 | 7 | 0 | 7 |
2010 | 6 | 0 | 6 |
2011 | 7 | 0 | 7 |
2012 | 6 | 1 | 7 |
2013 | 10 | 2 | 12 |
2014 | 8 | 3 | 11 |
2015 | 9 | 2 | 11 |
2016 | 14 | 2 | 16 |
2017 | 18 | 0 | 18 |
2018 | 5 | 2 | 7 |
2019 | 15 | 3 | 18 |
2020 | 13 | 3 | 16 |
2021 | 12 | 1 | 13 |
2022 | 12 | 0 | 12 |
2023 | 11 | 0 | 11 |
2024 | 7 | 1 | 8 |
2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neuroblastoma" by people in Profiles.
-
Hyperleukocytosis in a neuroblastoma patient after treatment with natural killer T cells expressing a GD2-specific chimeric antigen receptor and IL-15. J Immunother Cancer. 2025 Jan 11; 13(1).
-
Characterization of Persister Cells Provides Insights into Mechanisms of Therapy Resistance in Neuroblastoma. Cancer Discov. 2024 Dec 02; 14(12):2308-2311.
-
Outcomes of patients with intermediate-risk neuroblastoma presenting with motor deficits relating to intraspinal tumor extension: A report from the Children's Oncology Group study ANBL0531. Pediatr Blood Cancer. 2025 Jan; 72(1):e31407.
-
Evaluation of Image-Defined Risk Factor (IDRF) Assessment in Patients With Intermediate-risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531. J Pediatr Surg. 2025 Jan; 60(1):161896.
-
Neuroblastoma Predisposition and Surveillance-An Update from the 2023 AACR Childhood Cancer Predisposition Workshop. Clin Cancer Res. 2024 Aug 01; 30(15):3137-3143.
-
A subset of image-defined risk factors predict completeness of resection in children with high-risk neuroblastoma: An international multicenter study. Pediatr Blood Cancer. 2024 Oct; 71(10):e31218.
-
Impact of risk-based therapy on late morbidity and mortality in neuroblastoma survivors: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2024 Jun 07; 116(6):885-894.
-
The KAT module of the SAGA complex maintains the oncogenic gene expression program in MYCN-amplified neuroblastoma. Sci Adv. 2024 May 31; 10(22):eadm9449.
-
Multifactoral immune modulation potentiates durable remission in multiple models of aggressive malignancy. FASEB J. 2024 May 31; 38(10):e23644.
-
Long-term follow-up of patients with intermediate-risk neuroblastoma treated with response- and biology-based therapy: A report from the Children's Oncology Group study ANBL0531. Pediatr Blood Cancer. 2024 Aug; 71(8):e31089.